News

Complete Response for Rizaport Versafilm to treat migraine.- IntelGenx Technologies

Read time: 1 mins

Published:29th Mar 2020

IntelGenx Technologies announced that it has received a Complete Response Letter (“CRL”) from the FDA regarding its resubmitted 505(b)(2) New Drug Application (“NDA”) for Rizaport VersaFilm for the treatment of acute migraines. The CRL states that the FDA cannot approve the application in its present form. The Agency requested additional information, but no new bioequivalence study.

Condition: Migraine/Headache

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Late-breaking data presented at AAN supporting long-term safety and efficacy of atogepant (Qulipta) for preventive treatment of migraine - AbbVie

AbbVie announced an interim analysis of an ongoing Phase III, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine.

2 mins

Drug news

Results published in The Lancet show Ubrelvy (ubrogepant) reduces the headache phase of a migraine attack when dosed during the prodrome of migraine

AbbVie announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of Ubrelvy (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack

3 min

Drug news

EU approves Aquipta for prophylaxis of migraine.- AbbVie

AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month

1 min

See all news